Abstract: A split cycle internal combustion engine comprises a combustion cylinder and a compression cylinder arranged to receive air and compress the air to provide a compressed working fluid to the combustion cylinder for combustion. The compression cylinder is coupled to a water reservoir. The engine further comprises a controller arranged to receive an indication of at least one parameter associated with the engine and/or a fluid associated therewith, and control delivery of the mass of water delivered to the compression cylinder based on the indication of the at least one parameter such that the total mass of water in the compressed working fluid at the end of the compression stroke results in a level of water concentration in the compressed working fluid that is less than a threshold water concentration level.

Abstract: A lanyard to hold a controller for a headset is provided. The lanyard includes a strap anchored on a top portion of a lid for a battery case of the controller, and a clip anchored to an opening pin in a bottom portion of the lid for the battery case of the controller. The strap includes a stretchable fabric and multiple sticky pads on an outer face that adhere to the stretchable fabric when the strap is looped around the clip. A headset using a controller that includes a lanyard as above, and the controller, are also provided.

Abstract: A method of treating selenium-containing wastewater comprises performing anoxic biological treatment of the selenium-containing wastewater to produce a first liquid including a residual dissolved selenium species, introducing an oxidant into the first liquid to form an oxidant-treated first liquid, introducing a coagulant into the oxidant-treated first liquid to form a second liquid having selenium-containing solids, and removing the selenium-containing solids from the second liquid in a solids-liquid separation operation.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: The present disclosure relates generally to the field of producing botulinum toxin. More specifically, the present disclosure relates to a method for producing botulinum toxin in a culture medium free or substantially free of animal product. The present disclosure also relates to the culture medium for producing botulinum toxin that is free or substantially free of animal product.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: Disclosed herein are methods of treatment of moderate to severe and very severe glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions. Also disclosed are liquid compositions of botulinum neurotoxin.

Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Abstract: A number of wave correction filters are disclosed which respond to power surges or spikes outside the intended frequency and/or voltage for a load device. The circuits respond to such undesired frequencies and voltage levels by sensing and separating them from the desired voltage and frequencies and connecting the energy from such undesired voltages and/or frequencies to resistors where it is dissipated as heat. In this way, the resulting energy is prevented from distorting the input voltage to the load device. It is also retained in the filter and prevented from traveling through a ground connection to pollute other related circuits.

Abstract: A number of wave correction filters are disclosed which respond to power surges or spikes outside the intended frequency and/or voltage for a load device. The circuits respond to such undesired frequencies and voltage levels by sensing and separating them from the desired voltage and frequencies and connecting the energy from such undesired voltages and/or frequencies to resistors where it is dissipated as heat. In this way, the resulting energy is prevented from distorting the input voltage to the load device. It is also retained in the filter and prevented from traveling through a ground connection to pollute other related circuits.

Abstract: The invention relates to a method for determining the quantity of pre-synaptic neuromuscular blocking substance (notably botulinum toxin) contained in a sample. In one aspects, the method comprises the following steps: (i) determining the minimum voltage Vm needed to induce the contraction of muscle tissue, said muscle tissue being connected to an electrical stimulator through a motor nerve and preferably immersed in an oxygenated physiological buffer containing glucose; (ii) adding the sample containing the pre-synaptic neuromuscular blocking substance; (iii) electrically stimulating, at a voltage at least equal to Vm, the muscle tissue at certain time intervals; (iv) comparing the effect induced by the sample to the effect induced by a reference substance and thereby determining the quantity of the pre-synaptic neuromuscular blocking substance in the sample.

Abstract: A waveform correction filter is connected into an alternating current power line to absorb and remove various forms of power pollution, including high-frequency spikes, surges and other forms of high-frequency oscillations, such as those which result from switching inductive loads on and off. The waveform correction filter of the invention includes a fuse and a coaxial amorphous toroidal inductor connected between a power line and neutral with a low-pass filter connected in series with the fuse and coaxial amorphous toroidal inductor. The filter includes a capacitor, a varistor connected in parallel with said capacitor, and a magnetic core inductor connected in series with each other and in parallel with the capacitor and said varistor. A lamp may be connected in series with the resistor and the magnetic core inductor or across the resistor. Various arrangements are shown for connecting a plurality of the waveform correction filters into single phase or three-phase Wine or delta circuits.